Search

About this release This release by Public Health Scotland (PHS) uses information from the National SACT dataset. This work was requested by the Scottish Medicines Consortium (SMC)...

About this release This release by Public Health Scotland (PHS) presents analyses carried out within the Population Health Monitoring programme to project unplanned acute inpatient...

The most up to date information on uptake and coverage of pneumococcal vaccination, alongside data on those who are eligible for vaccination.

The aim of this work is to capture real-world evidence from Scotland to support Health Technology Assessment by the Scottish Medicines Consortium.

The aim of this work is to capture real-world evidence from Scotland to support Health Technology Assessment by the Scottish Medicines Consortium.

About this release This publication by the Cancer Medicines Outcomes Programme-Public Health Scotland collaboration reports on the outcomes of patients in Scotland who received...

This is the annual publication of people supported through care at home services where the support is provided or funded by the local authorities in Scotland.

The aim of this work was to capture real-world evidence from Scotland on the use of maintenance poly (ADP-ribose) polymerase inhibitor (PARPi) Systemic Anti-Cancer Therapy (SACT) of adult patients with advanced high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, following completion of first-line platinum-based chemotherapy. The Scottish Medicines Consortium (SMC) requested this work which describes current SACT use in this population. This work will assist SMC members when considering submissions for rucaparib (SMC2799).

The aim of this work was to capture real-world evidence from Scotland to support Health Technology Assessment by the Scottish Medicines Consortium. First-line treatment of adults with advanced non-small-cell lung cancer (NSCLC) whose tumours have presumed EGFR mutations: information for SMC decision SMC2736

The aim of this work is to capture real-world evidence from Scotland to support Health Technology Assessment by the Scottish Medicines Consortium.